Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. SinoMab BioScience Limited
  6. Summary
    3681   HK0000544194

SINOMAB BIOSCIENCE LIMITED

(3681)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
10/21/2021 10/22/2021 10/25/2021 10/26/2021 10/27/2021 Date
2.89 2.91 2.9 2.81 2.81 Last
13800 28500 300 153300 600 Volume
-1.37% +0.69% -0.34% -3.10% 0.00% Change
Estimated financial data (e)
Sales 2019 - - -
Net income 2019 -276 M -43,3 M -43,3 M
Net cash position 2019 1 154 M 181 M 181 M
P/E ratio 2019 -9,58x
Yield 2019 -
Sales 2020 12,8  2,00  2,00 
Net income 2020 -123 M -19,2 M -19,2 M
Net cash position 2020 818 M 128 M 128 M
P/E ratio 2020 -31,8x
Yield 2020 -
Capitalization 2 321 M 364 M 364 M
EV / Sales 2019 -
EV / Sales 2020 241 175 561x
Nbr of Employees 262
Free-Float 30,4%
More Financials
Company
SinoMab BioScience Limited is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE). The CompanyÔÇÖs product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is developing drugs... 
Sector
Pharmaceuticals
Calendar
03/28Earnings Release
More about the company
All news about SINOMAB BIOSCIENCE LIMITED
09/17EVEREST MEDICINES : Wins License to Kidney Disease Treatment; Shares Rise 4%
MT
09/16SINOMAB BIOSCIENCE : Sinovent and Everest Medicines Announce Licensing Agreement for Globa..
AQ
09/16Everest Medicines, Suzhou Sinovent Pharmaceuticals Co. Ltd. and SinoMab BioScience Limi..
CI
08/24SINOMAB BIOSCIENCE : Widens Losses in H1
MT
08/23Sinomab Bioscience Limited Reports Earnings Results for the Half Year Ended June 30, 20..
CI
06/25SINOMAB BIOSCIENCE : China Authorizes SinoMab's Lupus Drug as Treatment for Another Autoim..
MT
06/23SINOMAB BIOSCIENCE : $13 Million Bond Issuance Deal with Potential Investor Falls Through
MT
05/12SINOMAB BIOSCIENCE : Proposed election of independent non-executive director and supplemen..
PU
05/12REVISED FORM OF PROXY FOR THE ANNUAL : 00 a.m.
PU
04/28FORM OF PROXY FOR THE ANNUAL GENERAL : 00 a.m.
PU
04/28SinoMab BioScience Limited Announces Earnings Results for the Year 2020
CI
03/22SINOMAB BIOSCIENCE : Unit Signs 20-Year Lease for Building in China's Hainan Province
MT
03/22Sinomab Bioscience Limited Reports Earnings Results for the Year Ended December 31, 202..
CI
03/22SINOMAB BIOSCIENCE : Announcement - connected transaction under lease agreement
PU
02/04SINOMAB BIOSCIENCE : to Sell $14 Million Shares of China Healthcare Fund
MT
More news
News in other languages on SINOMAB BIOSCIENCE LIMITED

- No features available -

More news
Chart SINOMAB BIOSCIENCE LIMITED
Duration : Period :
SinoMab BioScience Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINOMAB BIOSCIENCE LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Shui On Leung Chairman & Chief Executive Officer
Jianping Hua Chief Financial Officer
Dylan Carlo Tinker Independent Non-Executive Director
Ping Cho Terence Hon Independent Non-Executive Director
George William Hunter Cautherley Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SINOMAB BIOSCIENCE LIMITED-38.91%364
CSL LIMITED4.53%101 238
WUXI BIOLOGICS (CAYMAN) INC.16.73%65 479
SAMSUNG BIOLOGICS CO.,LTD.6.42%49 817
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.10.24%39 826